PLPL - Plandaí Biotechnology, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.011
+0.001 (+9.45%)
At close: 3:56PM EDT
Stock chart is not supported by your current browser
Previous Close0.010
Open0.012
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.009 - 0.012
52 Week Range0.009 - 0.030
Volume3,251,786
Avg. Volume2,286,009
Market Cap2.052M
Beta-1.21
PE Ratio (TTM)N/A
EPS (TTM)-0.025
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    Plandaí Biotechnology to Focus on International Nutraceutical Cannabis Opportunities

    Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today discussed its focus on developing the international nutraceutical market for its full-profile, non-psychoactive cannabis extract. The international market for nutraceutical or wellness products is expected to reach $302,306 million by 2022 from $184,092 million in 2015, with an annual growth rate of 7.04% from 2016 to 2022. Recent innovations and findings of function-specific antioxidants are expected to create new opportunities in the international sector,  and the Company believes its highly bioavailable, full-profile, non-psychoactive cannabis extract will play a role in this emerging growth market.

  • GlobeNewswire8 days ago

    Plandai Biotechnology Discusses Cannabis Extract Opportunities and Research Potential

    Vision is to Produce World’ s Only Full-Profile Non-Psychoactive Cannabis Extract. LONDON, UNITED KINGDOM, June 14, 2018-- Plandaí Biotechnology, Inc., producer of the highly bioavailable Phytofare ® catechin ...

  • GlobeNewswire10 days ago

    Plandai Biotechnology Discusses Potential for Using Phytofare in Treating Type II Diabetes

    Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today discussed the potential benefits of using highly-bioavailable green tea catechins, like those found in the Company’s proprietary Phytofare® extract, in treating people suffering from Type II diabetes.   Worldwide as of 2013, 382 million people, or 8.3% of the adult population, have diabetes, with Type II Diabetes making up about 90% of the cases.  In 2014, the International Diabetes Federation estimated that diabetes resulted in 4.9 million annual deaths. Callum Cottrell-Duffield, Chief Operating Officer of Plandai, commented, “Diabetes is now the leading cause of death in South Africa and the rates are only climbing through much of sub-Sahara Africa and the developing world where fat-rich foods have supplanted traditional diets.

  • GlobeNewswire23 days ago

    Plandai Biotechnology’s SORBEO Phytofare Reports Positive Results in Chicken Studies

    Plandai Biotechnology, Inc. (OTC Markets: PLPL) (the “Company” or “Plandai”), a producer of nutraceutical and highly phyto-available extracts, is pleased to report positive results from chicken studies on how Phytofare® infused SORBEO™ is beneficial as a feed additive in poultry diets. The studies examined the benefits of Phytofare® when delivered in a low dosage formulated in liposome iotas, then added to feed formulations which were fed to the control groups of chickens.

  • GlobeNewswire29 days ago

    Plandai Biotechnology Announces Origine 8 Wins Prestigious Natural & Organic Products Award

    Natural & Organic Products Europe is Europe’s biggest trade show for natural & organic products, making it the ‘must attend’ event for buyers of natural health and living products, natural and organic food & drink as well as natural beauty & personal care products. Awards are given out annually highlighting the very best products, individuals and stores throughout the continent.

  • GlobeNewswirelast month

    Plandai Biotechnology’s Phytofare® Green Tea Catechins as a Phytogenic Substance in Poultry Diets

    Based on the results of published studies, the addition of generic green tea catechins to the diets of both broilers and layers has been shown to improve the productive performance and reduce the cholesterol content in the serum and egg yolk, implying its potential effect on egg-quality parameters. Furthermore, the addition of generic green tea catechins in the chickens’ diet decreases all microflora counts in the caecum due to an antibiotic-like effect. In this review, it was found that green tea catechins’ inclusion in broiler diets had positive effects on growth performance and lean meat production, whereas catechins in high dosage tended to decrease feed intake and body weight gain but delivered an improved feed conversion ratio.

  • GlobeNewswirelast month

    Plandai Biotechnology Addresses Opportunities in the South African and Global Poultry Industries

    Plandai Biotechnology Inc. (OTC Markets: PLPL) (the “Company” or “Plandai”), a producer of nutraceutical and highly phyto-available extracts, is pleased to provide background on the current known issues in the global poultry industry and its identification of potential opportunities. Globally, more than 58 billion chickens are raised annually as a source of food, for both their meat and eggs. Chicken producers use nationally approved medications, such as antibiotics and antivirals in feed or drinking water, to treat disease or to prevent disease outbreaks.  As a result of the ban on the use of antibiotic growth promoters in animal diets in the European Union as from January 2006, and the growing pressure on poultry producers in other parts of the world, alternative substances and strategies for animal health and growth promotion are now necessary.

  • GlobeNewswirelast month

    Plandai Biotechnology’s Phytofare Gaining Traction in International Markets

    Plandai Biotechnology, Inc. (OTC Markets: PLPL) (the “Company” or “Plandai”), a producer of nutraceutical and highly phyto-available extracts, is pleased to provide an update on its successful roll-out of its Phytofare® supplement. Plandaí Biotech’s Phytofare®, is the only clinically proven green tea extract shown to be bioavailable. Generic green tea extracts are thought to have bioavailability of between 1-10% whereas Phytofare® has shown in a human bioavailability study to have a bioavailability of 10 times that of generic green tea extract.

  • GlobeNewswire2 months ago

    Plandai Biotechnology’s Phytofare® Utilizes Green Tea to Fight Type 2 Diabetes

    Plandai Biotechnology Inc. (OTC Markets: PLPL) (the “Company” or “Plandai”), a producer of nutraceutical and highly phyto-available extracts, is pleased to provide an update to its Phytofare solution as a preventive mitigation against Type 2 diabetes. In looking for a natural solution, epidemiological studies indicate that populations with a high intake of green tea catechins benefit in terms of reduced body weight, body fat, the balance of insulin and glucagon, maintaining blood glucose, and cardiovascular health.

  • GlobeNewswire2 months ago

    Plandai Biotechnology Discusses How Green Tea Combats Type 2 Diabetes

    Plandai Biotechnology Inc. (OTC Markets: PLPL) (the “Company” or “Plandai”), a producer of nutraceutical and highly phyto-available extracts, is pleased to discuss green tea and its positive natural attributes in helping to prevent and fight Type 2 diabetes. Generally, diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. Insulin is a hormone that regulates blood sugar.

  • GlobeNewswire2 months ago

    Plandai Biotechnology Provides Background on its Past and Present Cannabis Initiatives

    Company History in Cannabis Research Dates Back to February 2013. LONDON, UNITED KINGDOM, April 25, 2018-- Plandai Biotechnology Inc., a producer of nutraceutical and highly phyto-available extracts, today ...

  • GlobeNewswire2 months ago

    Plandai Biotechnology Discusses Cannabis Strategy, Research and Business

    Plandai Biotechnology Inc. (OTC Markets: PLPL) (the “Company” or “Plandai”), a producer of nutraceutical and highly phyto-available extracts, is pleased to provide an update on its cannabis business strategy and opportunities. Using the Company’s proprietary processing technology, Plandaí intends to establish that it can produce a full-profile cannabis extract, Phytofare® Cannabis Complex, that contains both CBD and the precursor acid form of THC found in live cannabis plant. Based on prior, successfully, published USD/Plandai bioavailability studies with oil based fruits, Plandaí’s hypothesis is that the resultant extract will have the superior bioavailability of other Phytofare® extracts with the added benefit of being non-psychoactive.

  • GlobeNewswire2 months ago

    Plandai Biotechnology Provides Update on its Convertible Debt

    Previously Issued Convertible Notes Now in Friendly Shareholder Hands. LONDON, UNITED KINGDOM, April 12, 2018-- Plandai Biotechnology Inc., a producer of nutraceutical and highly phyto-available extracts, ...

  • GlobeNewswire2 months ago

    Plandai Biotechnology Addresses Bioavailability and the Science of Phytofare

    Human Clinical Trial Results and Key Benefits. Phytofare Catechin Complex is Superior to Generic Green Tea Extracts. LONDON, UNITED KINGDOM, April 10, 2018-- Plandai Biotechnology Inc., a producer of nutraceutical ...

  • GlobeNewswire3 months ago

    Plandai Biotechnology Provides Update to Its Proprietary Technology

    Phytofare Clinically Proven to Dramatically Improve Absorption. LONDON, UNITED KINGDOM, April 03, 2018-- Plandai Biotechnology Inc., a producer of nutraceutical and highly phyto-available extracts, today ...

  • GlobeNewswire3 months ago

    Plandai Biotechnology Appoints Paritz & Company as New Auditor

    Performing Two Year Audit for Plandaí to Become Current and SEC Compliant. LONDON, UNITED KINGDOM, March 27, 2018-- Plandaí Biotechnology Inc., a producer of nutraceutical and highly phyto-available extracts, ...